- Investing.com
Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It is also developing THB335, an oral small molecule KIT inhibitor for the treatment of mast cell-mediated skin, respiratory, and gastrointestinal conditions. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was incorporated in 2019 and is headquartered in San Francisco, California.
Pioneering Therapy | Third Harmonic Bio's THB335, an oral wild-type KIT inhibitor, shows promise in treating mast-cell driven diseases, addressing an untapped area in inflammation and immunology |
Market Potential | Analysts estimate peak US sales for chronic spontaneous urticaria at $2.7 billion, highlighting the significant commercial opportunity for THB335 |
Explore Clinical Progress | THB335's accelerated development timeline, with Phase 1 data expected in Q1 2025, positions Third Harmonic Bio for rapid advancement in the competitive biotech landscape |
Financial Strength | With $255.3 million in cash and a current ratio of 42.5, Third Harmonic Bio is well-positioned to fund operations through 2026, supporting its ambitious clinical programs |
Metrics to compare | THRD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTHRDPeersSector | |
---|---|---|---|---|
P/E Ratio | −5.6x | −1.1x | −0.6x | |
PEG Ratio | 0.70 | 0.00 | 0.00 | |
Price/Book | 0.7x | 0.9x | 2.6x | |
Price / LTM Sales | - | 5.6x | 3.1x | |
Upside (Analyst Target) | 291.8% | 287.6% | 47.1% | |
Fair Value Upside | Unlock | 12.4% | 8.1% | Unlock |